IGHE and neoplasm: It is demonstrated for the first time that mice expressing HER2/neu+ tumors injected with HER2/neu IgE-sensitized ADMC have significantly reduced tumor size and increased survival rates (>30%) compared to those labelled with non-specific IgE (Figures 5C, D).